EWTX — Edgewise Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1710072 ·
Last close
$42.04
Market Cap
$4.60B
52W High
$48.78
52W Low
$19.76
ADV30
1,601,037
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -46,143,000 1,166,151,000 1,780,020,000 68,680,000 147,352,000
Jun 2026 0 — -61,943,000 -57,327,000 479,688,000 72,319,000 31,611,000
Mar 2026 0 — -54,115,000 -49,013,000 518,522,000 33,211,000 25,319,000
Dec 2025 0 — -55,979,000 -50,216,000 552,603,000 61,148,000 30,346,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-201,895,000
Investing CF
$190,360,000
Financing CF
$34,212,000
CapEx
$-382,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$8.19
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$513,440,000
Inventory
—
Receivables
—
ST Investments
$1,675,213,000
EBIT TTM
$-218,180,000
Pretax Income TTM
$1,164,928,000
Interest Exp TTM
—
Analysts
12

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -191,406,000 -167,795,000 552,603,000 30,346,000 522,257,000 -143,816,000
Dec 2024 0 -158,832,000 -133,813,000 486,817,000 27,601,000 459,216,000 -109,028,000
Dec 2023 0 -114,357,000 -100,163,000 340,035,000 21,205,000 318,830,000 -91,948,000
Dec 2022 0 -71,658,000 -67,640,000 367,101,000 20,385,000 346,716,000 -52,635,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-197,222,000
OpCashFlow TTM
—
Assets (Latest)
$479,688,000
Forward EPS
$-1.75

Max Pain — expiry 2026-12-18

max pain strike: $40.00 · spot: $41.37 · call oi: 7,470 · put oi: 932

Peers — same industry

TickerNameMarket CapLastDaily %
KNSA Kiniksa Pharmaceuticals International, plc $4.64B $95.11 —
GIKLY Grifols SA $4.69B $5.55 —
IONS IONIS PHARMACEUTICALS INC $4.49B $26.96 —
COGT Cogent Biosciences, Inc. $4.85B $27.85 —
ERAS Erasca, Inc. $4.87B $13.89 —

News headlines (Yahoo Finance, 1h cache)

/C O R R E C T I O N - Edgewise Therapeutics/
2026-11-09 16:41 · Yahoo
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
2026-11-09 13:00 · Yahoo
Why Edgewise Therapeutics Stock Is In Focus After Phase 3 Filing For Heart Drug
2026-11-07 13:16 · Yahoo
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
2026-11-05 13:00 · Yahoo
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
2026-11-04 21:01 · Yahoo
Servier’s $1.55bn muscular dystrophy drug fails Phase II BMD trial
2026-11-04 12:35 · Yahoo
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
2026-11-02 13:00 · Yahoo
Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says
2026-10-27 15:53 · Yahoo
Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
2026-10-15 02:11 · Yahoo
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
2026-10-08 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.